Growth hormone + Growth hormone treatment and puberty
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypothyroidism
Conditions
Hypothyroidism
Trial Timeline
May 1, 2003 → Nov 1, 2011
NCT ID
NCT00206375About Growth hormone + Growth hormone treatment and puberty
Growth hormone + Growth hormone treatment and puberty is a approved stage product being developed by Eli Lilly for Hypothyroidism. The current trial status is terminated. This product is registered under clinical trial identifier NCT00206375. Target conditions include Hypothyroidism.
What happened to similar drugs?
1 of 1 similar drugs in Hypothyroidism were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00206375 | Approved | Terminated |
Competing Products
5 competing products in Hypothyroidism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Armour Thyroid + Levothyroxine | AbbVie | Phase 2/3 | 45 |
| iodinated contrast agents | Bayer | Pre-clinical | 23 |
| Iohexol + Iodixanol + Iopromide + Ioversol | Bayer | Approved | 32 |
| Iodinated contrast agents | Bayer | Pre-clinical | 23 |
| levothyroxine sodium | Xeris Pharmaceuticals | Phase 2 | 29 |